B. A. Orr

A spatial cell atlas of neuroblastoma reveals developmental, epigenetic and spatial axis of tumor heterogeneity

This paper creates a spatial cell atlas of neuroblastoma, revealing tumor heterogeneity through multi-omics data and identifying spatial compartmentalization and signaling patterns.

Mapping pediatric brain tumors to their origins in the developing cerebellum

The paper maps the cellular origins of three common pediatric brain tumors using a single-nucleus atlas and transcriptome data, identifying lineage-specific origins and potential therapeutic targets.

The Myogenesis Program Drives Clonal Selection and Drug Resistance in Rhabdomyosarcoma

This study shows that targeting developmental states in rhabdomyosarcoma can prevent disease recurrence by eliminating myoblast-like cells and inhibiting EGFR-dependent paraxial mesoderm populations.

Patient-Derived Orthotopic Xenografts and Cell Lines from Pediatric High-Grade Glioma Recapitulate the Heterogeneity of Histopathology, Molecular Signatures, and Drug Response

The paper establishes patient-derived orthotopic xenograft models and cell lines from pediatric high-grade glioma that replicate histopathology, molecular signatures, and drug response, providing a resource for research.

St. Jude Cloud a Pediatric Cancer Genomic Data Sharing Ecosystem

St. Jude Cloud provides a genomic data sharing ecosystem for pediatric cancer research, offering access to over 10,000 patient genomes and enabling analysis of cancer subtypes and mutational signatures.

Functional loss of a non-canonical BCOR-PRC1.1 complex accelerates SHH-driven medulloblastoma formation

This study shows that loss of BCOR in SHH-medulloblastoma accelerates tumor formation by disrupting the BCOR-PRC1.1 complex and increasing Igf2 expression.

Comprehensive molecular characterization of pediatric treatment-induced high-grade glioma: A distinct entity despite disparate etiologies with defining molecular characteristics and potential therapeutic targets

This study characterizes treatment-induced high-grade gliomas (TIHGGs) through molecular profiling, identifying distinct subgroups and potential therapeutic targets.